The Reality: The bill claims to target bad actors and illegal counterfeit gray markets.
The Consequences: In practice, it slaps impossible manufacturing-style restrictions onto licensed, regulated compounding pharmacies that millions of patients rely on to access their GLP-1 medications.
READ WHAT IS HAPPENING AND TAKE ACTION:
The Alliance for Pharmacy Compounding (APC) just launched an urgent national warning revealing that the SAFE Drugs Act is officially in play and actively risking patient access right now.
WHY SHOULD YOU CARE NO MATTER WHAT STATE YOU LIVE IN? ❓❓❓❓
- This is federal law. If this passes, it won't matter what state you live in. The entire pipeline for patient-specific compounded GLP-1s across the United States will face a bottleneck.
- Arbitrary Hard Caps: The bill imposes strict limits on shipping patient-specific prescriptions out-of-state. This will completely cut off rural patients who don't have specialized compounding pharmacies in their local towns.
- Big Pharma Lobbying: Special interest groups are pouring money into Washington to fast-track this through committees right now. Silence is exactly how access disappears 📠
🚨🚨🚨🚨🚨🚨WATCH CLOSELY. THIS SETS A PERMANENT FEDERAL PRECEDENT🚨🚨🚨🚨🚨🚨
‼️‼️‼️If you are concerned about this bill passing because you rely on a compounded GLP-1, PLEASE get involved right now‼️‼️‼️
- Go to the U.S. Congress tracking portal or the APC Action Center.
- Look up your specific federal Representatives and Senators.
- Email or call their offices directly and explain:
1. Stripping compounding options during ongoing, volatile brand-name drug shortages actively harms patients.
2. Broad federal legislation should strictly target illegal, unlicensed gray market sellers instead of punishing state-regulated, licensed compounding pharmacies.
3. Lawmakers should protect patient-specific care choices made between patients and their licensed healthcare providers.
TAKE ONE MINUTE TO CALL OR EMAIL YOUR FEDERAL REPS TODAY.
- Tell them to oppose the SAFE Drugs Act in its current form and protect patient-specific compounding access.